أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - dexamethasonum fosfat - augndropar, dreifa - 1 mg/ml

أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - neomycinum súlfat; polymyxinum b súlfat; dexamethasonum fosfat - augndropar, dreifa

أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

galderma nordic ab - doxycyclinum inn - hart hylki með breyttan losunarhraða - 40 mg

أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - dexamethasonum fosfat; tobramycinum inn - augndropar, dreifa

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

accord healthcare s.l.u. - dabigatran etexilate mesilate - venous thromboembolism; arthroplasty, replacement - blóðþurrðandi lyf - prevention of venous thromboembolic events.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glycogen geymsluskammt tegund ii - Önnur meltingarvegi og efnaskipti vörur, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

amicus therapeutics europe limited - miglustat - glycogen geymsluskammt tegund ii - Önnur meltingarfæri og umbrotsefni - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).